Clinician’s Brief spotlights practical OA pain management

Clinician’s Brief has added another entry to the growing body of industry-sponsored osteoarthritis education with “Practical Advice on Managing Osteoarthritis Pain With Dr. Downing,” a Partner Podcast sponsored by PRN Pharmacal and listed as episode 357 in the outlet’s orthopedics section. The episode features Dr. Robin Downing, a well-known veterinary pain specialist, and centers on practical management of osteoarthritis-associated pain and inflammation. (cliniciansbrief.com)

The timing fits a broader shift in companion animal OA care. Over the past several years, veterinary guidance has moved away from viewing osteoarthritis as a condition managed by analgesics alone. AAHA’s 2022 pain management guidelines emphasize thorough assessment, multimodal therapy, regular reassessment, nonpharmacologic interventions, and client education as core parts of chronic pain care. In parallel, Clinician’s Brief and other veterinary education outlets have increasingly focused on earlier OA recognition, mobility screening, and long-term management plans rather than waiting for severe impairment. (aaha.org)

That broader context matters because the therapeutic landscape is more crowded than it was even a few years ago. Traditional NSAIDs remain foundational in many canine OA protocols, but anti-NGF monoclonal antibodies have become part of first-line discussions in current literature and guidelines. A 2025 Frontiers in Veterinary Science trial comparing bedinvetmab with meloxicam in 101 dogs found both groups improved significantly over baseline, with no statistically significant efficacy difference between products over the 56-day study period. The bedinvetmab group had fewer reported adverse events and a higher study completion count, though the authors and sponsor both note the study was small and short, limiting conclusions about safety differences. (frontiersin.org)

Sponsored educational content from Clinician’s Brief reflects that same multimodal framing. In a separate OA-focused article, the publication notes that early intervention may include weight management, exercise, and polysulfated glycosaminoglycan therapy, alongside first-line pain-control options such as NSAIDs and monoclonal antibody therapy. That aligns with the kind of practical, layered decision-making many general practices are already using: matching drug choice to comorbidities, tolerance, pet parent adherence, and whether the clinic can support rehab, nutrition counseling, and serial reassessment. (cliniciansbrief.com)

Expert commentary available in the published literature points in the same direction. The 2025 comparative bedinvetmab study states that current AAHA, WSAVA, and COAST guidance all support NSAIDs and anti-NGF monoclonal antibodies as first-line options for canine OA pain. Zoetis, in its summary of the study, framed the results as clinically useful for treatment selection, while Movement Referrals’ Professor James Innes said the head-to-head data are valuable for veterinarians and pet parents making decisions. That should be read with appropriate caution because the company sponsored the trial, but it still adds to the comparative evidence base clinicians have been asking for. (frontiersin.org)

Why it matters: For veterinary professionals, this story is less about a breakthrough than about the normalization of multimodal OA care in clinical education. Sponsored podcasts like this one can influence how busy clinicians think about sequencing therapy, especially in general practice where OA cases are frequent and time is limited. The practical takeaway is that chronic OA pain management increasingly depends on structured reassessment, pet parent communication, and combining pharmacologic and nonpharmacologic tools rather than relying on a single product category. That includes recognizing when mobility loss reflects not just pain intensity, but also muscle loss, joint pathology, excess weight, or limited home adherence. (aaha.org)

There’s also a business and workflow angle. Multimodal OA care often requires more touchpoints: screening, baseline diagnostics when indicated, follow-up pain scoring, mobility coaching, nutrition conversations, and adverse-event monitoring. For practices, that can mean a larger role for technicians, standardized OA protocols, and clearer educational tools for pet parents. In other words, the clinical message in this podcast is likely to resonate because it matches where small animal practice is already heading. (aaha.org)

What to watch: The next phase in canine OA management will likely be shaped by more head-to-head comparative trials, continued debate over patient selection for NSAIDs versus monoclonal antibodies, and growing interest in earlier, disease-focused intervention before mobility decline becomes severe. Educational content like this podcast will probably keep tracking that shift, especially as practices refine repeatable OA care pathways. (frontiersin.org)